Intra-aortic balloon pump counterpulsation: are we optimizing the management of cardiogenic shock?

Abstract

Intra-aortic balloon pump counterpulsation (IABPC) has been used in various forms for decades. The change in physiology brought about by their use is conceptually appealing in managing cardiogenic shock and mechanical complications of myocardial infarction. A common myth is that this method of managing acute cardiological emergencies is to be limited to the realms of this specialist field. However, as medical physicians an appreciation and understanding of this novel therapy is essential not only as a lifesaving measure but also as a bridging therapy to more definitive management in the acute medical setting. IABPC is a safe and under-utilized technique despite featuring in all major international guidelines (ESC and ACC) for the management of cardiogenic shock secondary to acute coronary syndromes. Without awareness of this intervention we may be suboptimally managing patients in the first instance. To improve awareness we examine the evidence supporting the use of the IABPC therapy and the contraindications to their use. Complications and advances in technology are also addressed.

IABP: history-evolution-pathophysiology-indications: what we need to know

“…The value of the balloon pump as a circulatory assist device in the treatment of cardiogenic shock is well established [ 55 – 57 ]. Singh et al [ 58 ] suggested criteria for which IABC would be most successful: Triple Vessel disease with moderately preserved left ventricular function and good distal targets.…”